What alternative therapies are available for a patient who cannot take Rubraca (niraparib)?

Alternative PARP Inhibitors to Rubraca (Rucaparib)

For patients who cannot take Rubraca, olaparib (300 mg twice daily) or niraparib (200-300 mg once daily) are the recommended alternative PARP inhibitors, with selection based on BRCA mutation status and clinical setting. 1, 2

Clinical Context Determines the Alternative

For Maintenance Therapy in Recurrent Ovarian Cancer (Second-Line or Greater)

If the patient has germline or somatic BRCA mutations and has not previously received a PARP inhibitor:

• Olaparib 300 mg twice daily (strong recommendation, Category 1) 1, 2
• Niraparib 200-300 mg once daily - Note: FDA-restricted to germline BRCA mutations only in the recurrent maintenance setting 2

Both agents demonstrate robust clinical benefit in BRCA-mutated disease with high-quality evidence supporting their use 1.

For Treatment of Recurrent Disease (Not Maintenance)

Important regulatory update: Long-term safety data revealed concerns about overall survival benefit when PARP inhibitors are used as active treatment (rather than maintenance) for recurrent disease 2.

• Rucaparib was voluntarily withdrawn for treating BRCA-mutated ovarian cancer after ≥2 prior lines of chemotherapy in June 2022 due to lack of OS benefit 2
• Olaparib was similarly withdrawn for this indication in August 2022 after final analysis of SOLO-3 showed no statistical difference in clinical responses or OS 2

Therefore, for recurrent disease treatment, platinum-based chemotherapy remains the preferred approach over PARP inhibitor monotherapy 2.

For First-Line Maintenance Therapy

In the frontline setting after primary platinum-based chemotherapy:

• Olaparib 300 mg twice daily (for BRCA-mutated disease)
• Niraparib 200-300 mg once daily (broader indication including non-BRCA mutated disease in first-line)
• Olaparib + bevacizumab combination (for patients with HRD-positive tumors or BRCA mutations) 1

The panel notes that patients most likely to benefit from PARP inhibitors are those who receive them in the frontline setting 2.

Key Dosing Differences Between Alternatives

• Olaparib: 300 mg twice daily (600 mg total daily dose) - requires twice-daily dosing 1
• Niraparib: 200-300 mg once daily - convenient once-daily dosing with individualized starting dose based on body weight and platelet count 1

Critical Regulatory Restrictions to Remember

The FDA has significantly restricted second-line maintenance indications 2:

• Rucaparib: Limited to germline or somatic BRCA mutations
• Niraparib: Limited to germline BRCA mutations ONLY (most restrictive)
• Olaparib: Limited to germline or somatic BRCA mutations

This means niraparib cannot be used for somatic-only BRCA mutations in the recurrent maintenance setting, making olaparib the preferred alternative to rucaparib for patients with somatic BRCA mutations 2.

Safety Considerations

All PARP inhibitors carry a risk of MDS/AML (approximately 1.6% across studies), with most cases occurring in patients with prior platinum exposure 3. Common hematologic toxicities include:

• Thrombocytopenia
• Neutropenia
• Anemia

Niraparib has particularly notable hematologic toxicity, with creatinine clearance <47 ml/min identified as a risk factor for severe hematologic adverse events 4. Consider dose reduction strategies and close monitoring.

When PARP Inhibitors Are Not Appropriate

If the patient:

• Has progressed on prior PARP inhibitor therapy
• Lacks BRCA mutations (in recurrent setting)
• Has platinum-resistant disease requiring active treatment

Then bevacizumab-based therapy or platinum-based chemotherapy regimens are more appropriate alternatives 1, 2. The combination of bevacizumab + PARP inhibitor is not recommended in the recurrent disease maintenance setting 2.

Practical Algorithm

1. Confirm BRCA mutation status (germline vs. somatic) using FDA-approved testing
2. Determine clinical setting: First-line maintenance vs. recurrent maintenance vs. active treatment
3. For recurrent maintenance with BRCA mutation:
   • Germline BRCA: Choose olaparib OR niraparib
   • Somatic BRCA only: Choose olaparib (niraparib not approved)
4. Assess renal function: If CrCl <47 ml/min, favor olaparib over niraparib due to hematologic toxicity risk 4
5. Consider patient preference: Once-daily (niraparib) vs. twice-daily (olaparib) dosing